ACCEPTREAD MORE Direct accesses Go to main menu Go to main content Contact Careers YOU ARE VIEWING THE WEBSITE IN ENGLISH EN FR Search the site WHO WE ARE OUR PRODUCTS & PIPELINE OUR TECHNOLOGIES INVESTORS & MEDIA COMPANY We are an innovative clinical-stage gene therapy company currently focused on discovering, developing and commercializing novel therapies for patients with severe retinal neurodegenerative diseases. ON THIS PAGE KEY FIGURES NEWS & MEDIA Home > Who we are > Company Our mission is to turn scientific advances in gene therapy into novel treatments for patients with severe degenerative diseases of the eye and the central nervous system. Our initial focus is on severe retinal diseases, with the goal of preserving or restoring vision in patients who suffer from sight-threatening ophthalmic diseases. We have been using an integrated development platform based on the combination of a gene therapy-based approach with technologies such as Mitochondrial Target Sequence (MTS) and optogenetics. We are proud of the two promising product candidates that, to date, have advanced to the stage of being tested in clinical trials. And we are investigating others. Our goal: to transform the lives of patients suffering from severe degenerative diseases of the eye and central nervous system Our gene therapy-based approach appeals to us not just because we are excited about bringing advanced, innovative science to bear on diseases with a severe impact on patients’ quality of life. Our approach also energizes us because it holds out the promise of a long-lasting cure administered in a manner that is simple and convenient for patients and their physicians. Thus, our two leading product candidates are currently designed to be administered in a single treatment to each eye by intravitreal, or IVT, injection. We have broader ambitions. We believe that our technology platforms have wide applicability, not just within ophthalmology but outside as well, potentially to other disorders of the central nervous system. Even as we push forward on getting our lead products to market, our research teams are exploring gene therapy-based therapy options for other neurodegenerative conditions for which no satisfactory solutions have been found. KEY FIGURES 2012 DATE OF INCORPORATION, PARIS, FRANCE 2 NUMBER OF PRODUCT CANDIDATES IN CLINICAL TRIALS 7 NUMBER OF STUDIES, COVERING CLINICAL TRIALS AND REGISTRIES, COMPLETED OR UNDERWAY FOR OUR PRODUCTS 41 NUMBER OF FULL-TIME EMPLOYEES ACROSS OUR TWO OFFICES (AS OF MARCH 2018) NEWS & MEDIA PRESS RELEASES EVENTS & PRESENTATIONS 01 December 2021 GenSight Biologics Announces Publication of Non-Human Primate Study Reporting Presence of LUMEVOQ® Vector DNA in Contralateral Eyes After Unilateral Injection 30 November 2021 GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US 22 November 2021 GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US ALL PRESS RELEASES PARIS NEW YORK CITY GENSIGHT BIOLOGICS S.A. 74, rue du Faubourg Saint-Antoine 75012 Paris FRANCE CONTACT US  © 2021 Gensight Biologics TERMS OF USE SITEMAP CONTACT CREDITS